Chemoinformaics analysis of (S)-4-(p-Tolyl)valeraldehyde
| Molecular Weight | 176.259 | nRot | 4 |
| Heavy Atom Molecular Weight | 160.131 | nRig | 7 |
| Exact Molecular Weight | 176.12 | nRing | 1 |
| Solubility: LogS | -3.125 | nHRing | 0 |
| Solubility: LogP | 2.957 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 29 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 13 | No. of Aromatic Carbocycles | 1 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 12 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 6 |
| nHA | 1 | APOL | 31.5107 |
| nHD | 0 | BPOL | 16.9193 |
| QED | 0.644 |
| Synth | 2.439 |
| Natural Product Likeliness | 0.626 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.038 |
| Pgp-sub | 0.002 |
| HIA | 0.003 |
| CACO-2 | -4.475 |
| MDCK | 0.0000183 |
| BBB | 0.955 |
| PPB | 0.567609 |
| VDSS | 2.804 |
| FU | 0.266555 |
| CYP1A2-inh | 0.844 |
| CYP1A2-sub | 0.944 |
| CYP2c19-inh | 0.709 |
| CYP2c19-sub | 0.845 |
| CYP2c9-inh | 0.286 |
| CYP2c9-sub | 0.767 |
| CYP2d6-inh | 0.489 |
| CYP2d6-sub | 0.871 |
| CYP3a4-inh | 0.228 |
| CYP3a4-sub | 0.466 |
| CL | 6.558 |
| T12 | 0.283 |
| hERG | 0.088 |
| Ames | 0.534 |
| ROA | 0.032 |
| SkinSen | 0.96 |
| Carcinogencity | 0.652 |
| EI | 0.991 |
| Respiratory | 0.864 |
| NR-Aromatase | 0.015 |
| Antiviral | No |
| Prediction | 0.666128 |